The net effect of l-opioid receptor agonists on intracranial self-stimulation (ICSS) in rats reflects an integration of rate-increasing and rate-decreasing effects. Previous opioid exposure is associated with tolerance to rate-decreasing effects and the augmented expression of abuse-related rate-increasing effects. This finding was replicated here with morphine. Subsequent studies then tested the hypothesis that opioid agonist-induced ratedecreasing effects require the activation of a larger relative fraction of l receptors, and hence are more vulnerable to tolerance-associated reductions in receptor density than rate-increasing effects. Two sets of experiments were conducted to test this hypothesis. First, the effects of morphine on ICSS were examined after pretreatment with the irreversible l antagonist b-funaltrexamine to reduce the density of available l receptors. Second, effects were examined for a range of l opioids that varied in relative efficacy at l receptors. The hypothesis predicted that (a) morphine, after b-funaltrexamine treatment, or (b) low-efficacy l agonists would mimic the effects of morphine tolerance to produce the reduced expression of rate-decreasing effects and enhanced expression of rate-increasing effects. Neither of these predictions were supported. These results indicate that l agonist-induced facilitation and depression of ICSS may be mediated by distinct populations of l receptors that respond differently to regimens of opioid exposure.
Introduction m-Opioid receptor agonists constitute one class of abused drugs (Hughes and Rieche, 1995; Cicero et al., 2007) , and intracranial self-stimulation (ICSS) is one of the preclinical experimental procedures that has been used to examine the abuse-related effects of m agonists and other drugs (Kornetsky and Esposito, 1979; Wise, 1998) . In ICSS, an operant response such as a lever press is maintained by the delivery of electrical stimulation to a brain region such as the medial forebrain bundle. Druginduced increases in low rates of ICSS are often interpreted as rewarding effects associated with the potential of abuse (Esposito et al., 1980; Cryan et al., 2003; Altarifi and Negus, 2011) . Evaluation of factors that determine the expression of drug-induced rate-increasing effects in ICSS may improve the usefulness of this procedure as an experimental tool for assessing the abuse potential of opioids and other drugs.
We have reported previously that the effects of morphine on ICSS in rats were determined by factors that included dose, time after morphine treatment, and the extent of previous morphine exposure (Altarifi and Negus, 2011) . Abuse-related rate-increasing effects of morphine were most apparent early after the administration of low morphine doses, and later in the time course after higher morphine doses, or after repeated morphine exposure. However, morphine also produced rate-decreasing effects that appeared to oppose and limit the expression of rateincreasing effects. These rate-decreasing effects of morphine were most apparent early in the time course after high morphine doses, and repeated morphine treatment produced tolerance to these rate-decreasing effects and a corresponding increase in the expression of rate-increasing effects. These results are in agreement with other studies in suggesting that the effects of morphine and other opioids on ICSS reflect an integration of both rate-increasing and rate-decreasing effects, and that opioid exposure can produce tolerance to ratedecreasing effects and increased expression of abuserelated rate-increasing effects (Lorens and Mitchell, 1973; Koob et al., 1975; Carlezon and Wise, 1993; Easterling and Holtzman, 1997) .
One possible explanation for these findings is that m agonist-induced facilitation of ICSS requires lower levels of receptor occupation and activation (i.e. has lower efficacy requirements and a higher receptor reserve) than m agonistinduced depression of ICSS. According to this hypothesis, lower morphine doses would produce sufficient receptor occupancy and activation to facilitate ICSS, whereas higher doses would produce higher levels of receptor occupancy sufficient to exert opposing rate-decreasing effects. Repeated morphine could selectively attenuate rate-decreasing effects and enhance the expression of rate-increasing effects by desensitizing and/or downregulating some fraction of m receptors to reduce the functional receptor density and attenuate the ability of morphine to produce rate-decreasing effects dependent on high levels of receptor occupancy (Martini and Whistler, 2007) .
The present study tested this hypothesis in two ways. First, the effects of morphine on ICSS were examined in different groups of rats after pretreatment with different doses of the irreversible m-opioid receptor antagonist b-funaltrexamine (b-FNA) (Ward et al., 1982; Walker et al., 1999; Bardo et al., 2003) . Because irreversible antagonists decrease the density of available receptors, the hypothesis predicted that b-FNA would be more potent to antagonize rate-decreasing than rate-increasing effects, and that it might be possible to titrate the b-FNA dose to selectively attenuate the rate-decreasing effects of morphine and enhance the expression of rate-increasing effects. Second, the effects on ICSS were examined for a range of other m agonists that varied in their relative efficacy at m receptors. The drugs tested were methadone, fentanyl, hydrocodone, buprenorphine, nalbuphine, and naltrexone (listed in order from the highest to the lowest efficacy as determined by in-vitro functional assays of agonist-stimulated GTPgS binding) (Selley et al., , 1998 Thompson et al., 2004) . The hypothesis predicted that higher efficacy m agonists would have sufficient efficacy to produce both morphine-like rate-increasing and rate-decreasing effects, but that lower efficacy m agonists might lack sufficient efficacy to produce rate-decreasing effects and might therefore produce enhanced rate-increasing effects.
Methods

Subjects and intracranial self-stimulation electrode implantation
Male Sprague-Dawley rats (Harlan Industries, Fredrick, Maryland, USA) weighing 310-350 g at the time of surgery were used for these studies. Rats were individually housed and maintained on a 12-h light/dark cycle with lights on from 6:00 to 18:00 h. Rats had free access to food and water, except during testing. Animal maintenance and research were carried out in compliance with National Institutes of Health guidelines on the care and use of animal subjects in research, and all animal-use protocols were approved by the Virginia Commonwealth University Institutional Care and Use Committee.
Rats were anesthetized with isoflurane gas (2.5-3% in oxygen; Webster Veterinary, Phoenix, Arizona, USA) for the implantation of stainless-steel electrodes. The cathode of each bipolar electrode (Plastics One, Roanoke, Virginia, USA) was 0.25 mm in diameter and covered with polyamide insulation, except at the flattened tip. The anode was 0.124 mm in diameter and uninsulated. The cathode was implanted in the left medial forebrain bundle at the level of the lateral hypothalamus (2.8 mm posterior and 1.7 mm lateral from the bregma, and 8.8 mm below the skull). The anode was wrapped around one of three skull screws to serve as the ground, and the skull screws and electrode assembly were secured with orthodontic resin. Animals were allowed to recover for at least 7 days before commencing ICSS training.
Experimental procedure Apparatus and training
Experiments were conducted in sound-attenuating chambers that contained modular acrylic test chambers (29.2 Â 30.5 Â 24.1 cm) equipped with a response lever (4.5 cm wide, extended 2.0 cm through the center of one wall, 3 cm off the floor), stimulus lights (three lights colored red, yellow, and green positioned 7.6 cm directly above the lever), a 2 W white house light, and an ICSS stimulator (Med Associates, St Albans, Vermont, USA). Electrodes were connected to the stimulator through bipolar cables and a commutator (Model SL2C, Plastics One). A computer and software (Med Associates) controlled the stimulator, programming parameters, and data collection.
Rats were trained under a continuous reinforcement schedule of brain stimulation, using procedures similar to those described previously (Pereira Do Carmo et al., 2009; Negus et al., 2010; Altarifi and Negus, 2011) . Each lever press resulted in the delivery of a 0.5-s train of square wave cathodal pulses (0.1 ms pulse duration), and stimulation was accompanied by illumination of the stimulus lights above the lever. Responses during the 0.5-s stimulation period did not result in additional stimulation. During the initial phase of training, sessions lasted 30-60 min, the frequency of stimulation was held constant at 158 Hz, and the stimulation intensity was adjusted to the lowest value that would sustain at least 30 stimulations/min. Once this criterion was fulfilled, frequency manipulations were introduced during sessions that consisted of sequential 10 min components. During each component, a descending series of 10 current frequencies (158-56 Hz in 0.05 log increments) was presented, with a 60-s trial at each frequency. A frequency trial began with a 5-s timeout, followed by a 5-s 'priming' phase, during which animals received five noncontingent stimulations with a 0.5-s interval between each stimulation. This noncontingent stimulation was followed by a 50-s 'response' phase, during which responding produced electrical stimulation under a continuous reinforcement schedule. Training continued with 3-12 sequential components per day, and the current intensity was adjusted until for the rest of the study. In addition, rats were habituated to saline injections until these injections had no effect on the ICSS frequency-rate curves. Once training and habituation to saline injections were completed, testing was initiated using the experimental designs described below.
Effects of repeated morphine and of b-funaltrexamine on cumulative morphine dose-effect curves
The first study was designed to compare the effects of repeated morphine with the effects of the irreversible m-opioid receptor antagonist b-FNA on the changes in ICSS produced by cumulative morphine dosing. Four groups of rats (n = 5 per group) received 0 (no pretreatment), 0.32, 1.0, or 3.2 mg/kg b-FNA 24 h before the determination of a cumulative morphine dose-effect curve. Cumulative morphine test sessions began with three consecutive 'control' ICSS components. The first control component was considered to be an acclimation component, and data from this component were discarded. Data from the second and third control components were used to calculate control parameters of frequency-rate curves for that session (see the Data analysis section). Immediately after the completion of these control ICSS components, cumulative morphine doses (0.32-10 mg/kg) were administered at 50-min intervals such that each sequential dose increased the total cumulative dose by 0.5 log units. Thirty minutes after each dose, ICSS was evaluated during two consecutive ICSS test components (10 min each, 20 min total). The group that received no b-FNA pretreatment was also used to evaluate the effects of repeated morphine treatment during a 14-day regimen of repeated morphine dosing and testing that began on the day after the determination of the initial cumulative morphine dose-effect curve. On days 1-6, sessions consisted of three consecutive control ICSS components, followed 30 min later by two test components, and 3.2 mg/kg morphine was administered immediately after the completion of the control components. On day 7, the cumulative morphine dose-effect curve was redetermined as described above. On days 8-13, sessions again consisted of three consecutive control components, followed 30 min later by two test components, and the daily morphine dose was increased to 10 mg/kg. On day 14, the cumulative morphine dose-effect curve was redetermined a second time.
Effects of opioid agonists with varying efficacies at the l receptor Methadone (0.032-5.6 mg/kg), fentanyl (0.001-0.1 mg/kg), hydrocodone (0.1-10 mg/kg), morphine (0.32-10 mg/kg), buprenorphine (0.001-0.1 mg/kg), nalbuphine (0.032-10 mg/kg), naltrexone (0.1 mg/kg) (in order from the highest to the lowest efficacy at m-opioid receptors), and vehicle (saline) were tested in one group of animals (n = 5). Morphine was tested first, and the results were similar to those reported previously (Altarifi and Negus, 2011) and to the results with cumulative morphine described above, and are not discussed further. The remaining drugs were tested in the order of buprenorphine, methadone, hydrocodone, fentanyl, nalbuphine, and naltrexone. For each drug, except naltrexone, testing was conducted in two phases. During the first phase, the dose was manipulated from doses that produced no effect on ICSS to doses that either (a) significantly decreased ICSS or (b) were at least 10 times greater than the lowest dose to significantly facilitate ICSS. Test sessions consisted of three consecutive control components, followed immediately by injection of the drug and then 30 min later by two consecutive test components. During the second phase, the time course of the dose producing peak facilitation of ICSS was determined. Test sessions consisted of three consecutive control components, followed immediately by injection of the drug and then by consecutive pairs of test components that began 10, 30, 100, 180, and 300 min after injection. Naltrexone was tested at a single dose (0.1 mg/ kg) alone and as a 20-min pretreatment to 1.0 mg/kg methadone. One rat died before studies with naltrexone; thus, these studies were carried out with only four rats.
Four other experiments were conducted in three other groups of rats to expand on the results obtained in the experiment described above. First, the time course of a higher buprenorphine dose (1.0 mg/kg) was determined in a group of six rats that had a history of intermittent nalbuphine injections (i.e. opioid testing no more than twice per week). Second, another group of four rats that had a history of intermittent methadone and loperamide injections received a high morphine dose (10 mg/kg) with or without pretreatment with nalbuphine (1.0 mg/kg). Nalbuphine (or saline) was injected 10 min before the injection of morphine, and ICSS was started 20 min after the administration of morphine. The remaining two experiments examined the effects of the highest efficacy m agonist methadone (0.032-3.2 mg/kg) and the lowest efficacy m agonist nalbuphine (0.032-10 mg/kg) in separate groups of opioid-naive rats. Table 1 summarizes all the groups used in this study.
In all experiments with different efficacy opioids, sessions were typically conducted on Tuesdays and Fridays and were separated by at least 3 days. This intermittent-dosing regimen was intended to minimize the development of tolerance to drug effects on ICSS. Training sessions consisting of three components were conducted on Mondays, Wednesdays, Thursdays, and occasionally, on Saturdays. In some cases, data from these training sessions were used to assess ICSS performance 24 h after injection in the timecourse studies. In these cases, data from the second and the third components of the training session were used as the '24-h time point' for data analysis.
Data analysis
The primary dependent variable was the reinforcement rate in stimulations/trial during each frequency trial. To normalize these raw data, reinforcement rates from each trial were converted into the percent maximum control rate (% MCR) for that rat on that day. The MCR was determined during the control components of each test session and was defined as the mean of the maximal rates observed in any frequency trial during the second and third control components. Thus, % MCR for each trial was calculated as (reinforcement rate during a frequency trialÄMCR) Â 100. Normalized data from the frequency trials of each pair of consecutive test components were then averaged across rats for display and for statistical analysis using two-way analysis of variance (ANOVA), with drug dose or time as one factor and ICSS frequency as the other factor. A significant ANOVA was followed by a Holm-Sidak post-hoc test, and the criterion for significance was set at P less than 0.05.
To provide an additional summary of ICSS performance, the total number of stimulations per component was calculated as the average of the total stimulations delivered across all 10 frequency trials of each component. Test data were expressed as a percentage of the total stimulations earned during the 'control' components (% control stimulations). Thus, % control stimulations for each test were calculated as (mean total stimulations during test componentsÄmean total stimulations during control components) Â 100.
To determine the effects of treatments on the MCRs and on the total stimulations during control components, data were analyzed as appropriate using paired t-tests or oneway repeated-measures ANOVA, followed by the Newman-Keuls post-hoc test. In each case, the criterion for significance was set at P less than 0.05.
Drugs
Morphine sulfate, b-FNA HCl, buprenorphine HCl, methadone HCl, hydrocodone bitartrate, naltrexone HCl, and fentanyl HCl were provided by the National Institute on Drug Abuse Drug Supply Program (Bethesda, Maryland, USA). Nalbuphine HCl was provided by Dr Kenner Rice (Chemical Biology Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA). All drugs were dissolved in saline and delivered subcutaneously in a volume of 1 ml/kg body weight. Table 2 and Fig. 1 show the control ICSS parameters and the effects of cumulative morphine before repeated morphine and after repeated daily treatment with 3.2 and 10 mg/kg morphine in the group receiving 0 b-FNA pretreatment. Under control conditions before cumulative morphine, little responding was maintained by the lower frequencies of stimulation (56-89 Hz), whereas the reinforcement rates increased at the intermediate and higher intensities (100-158 Hz). Before repeated morphine, testing with cumulative morphine produced dosedependent changes in ICSS ( Fig. 1a and b ). The lowest cumulative dose of 0.32 mg/kg morphine exerted no effect on ICSS. Treatment with 1.0 mg/kg morphine increased ICSS at the intermediate frequency of 100 Hz. Cumulative 3.2 mg/kg morphine produced a biphasic effect, increasing ICSS at intermediate frequencies (89 and 100 Hz), but decreasing ICSS at the highest frequency (158 Hz). Cumulative 10 mg/kg morphine exclusively produced rate-decreasing effects at intermediate to high frequencies (100-158 Hz) and almost eliminated ICSS.
Results
Effects of repeated morphine and of b-funaltrexamine on cumulative morphine dose-effect curves
Repeated 3.2 mg/kg/day morphine did not significantly alter the control ICSS parameters determined 24 h after the last repeated morphine dose and before testing with 'Intermittent' indicates that the drug was administered no more often than twice per week. b-FNA, b-funaltrexamine. Role of opioid efficacy in ICSS Altarifi et al. 681 
Effects of repeated morphine on cumulative morphine dose-effect curves. Cumulative morphine dose-effect curves were determined before repeated daily morphine administration (a, b), following 6 days of repeated daily administration of 3.2 mg/kg morphine (c, d), and 6 days of repeated daily administration of 10 mg/kg morphine (e, f). The left column (panels a, c, and e) shows the ICSS frequency-rate curves. Horizontal axes: frequency of electrical brain stimulation in Hz (log scale). Vertical axes: ICSS rate expressed as percent maximum control rate (% MCR). Data obtained for 0.32 mg/kg morphine, which had no effect under any conditions tested, were excluded from the graph for clarity, but were included in statistical analyses. Filled symbols indicate the frequencies at which morphine ICSS rates were different than those obtained during control components, as determined by the Holm-Sidak post-hoc test following a significant two-way ANOVA. cumulative morphine ( Table 2 ). The effects of cumulative morphine after a repeated daily treatment with 3.2 mg/kg/day are shown in Fig. 1c and d . The lowest cumulative dose of morphine, 0.32 mg/kg, again exerted no effect on ICSS. Cumulative 1.0 mg/kg morphine exclusively produced rate-increasing effects, but did so at more frequencies (89-112 Hz) than during the test conducted before repeated morphine. Similarly, cumulative 3.2 mg/kg morphine exclusively produced rateincreasing effects (89-112 Hz) during this test, which is in contrast to the biphasic effects of this dose before repeated morphine. Responding was again largely eliminated by cumulative 10 mg/kg morphine.
Repeated 10 mg/kg/day morphine decreased the control ICSS determined 24 h after the last repeated morphine dose, as indicated by a decrease in the total control number of stimulations per component ( Table 2 ). The effects of cumulative morphine are shown in Fig. 1e and f. Cumulative 0.32 mg/kg again exerted no effect. As was the case following the repeated administration of 3.2 mg/kg/day morphine, only rate-increasing effects were produced by cumulative 1.0 mg/kg (126 Hz) and 3.2 mg/kg (100-126 Hz) morphine. Cumulative 10 mg/kg morphine again produced only rate-decreasing effects, but these effects were attenuated such that decreases were only observed at the two highest frequencies (141-158 Hz). There was also a trend toward rate-increasing effects at the lower frequencies (71-100 Hz) that did not reach statistical significance. Overall, repeated morphine had three general effects: it decreased the control ICSS before cumulative morphine, enhanced the expression of cumulative morphine-induced facilitation of ICSS, and reduced the expression of cumulative morphine-induced rate-decreasing effects. Table 3 and Fig. 2 show that b-FNA pretreatment did not mimic the effects of repeated morphine. No dose of b-FNA altered the control parameters of ICSS (Table 3) , and b-FNA reduced both the rate-increasing and the rate-decreasing effects of cumulative morphine. b-FNA was most potent in antagonizing the rate-increasing effects of morphine, and morphine failed to exert significant rate-increasing effects at any frequency after any b-FNA dose. The low dose of 0.32 mg/kg b-FNA failed to antagonize the rate-decreasing effects of cumulative 3.2 or 10 mg/kg morphine ( Fig. 2a and b ), but higher doses of 1.0-3.2 mg/kg b-FNA dose-dependently eliminated the rate-decreasing effects of cumulative 3.2 and 10 mg/kg morphine ( Fig. 2c-f ).
Effects of opioid agonists with varying efficacies at the l receptor
The control parameters of ICSS did not vary significantly during sequential testing with m-opioid receptor ligands in a group of five rats, and the overall mean control parameters of this group are shown in Table 4 . The highefficacy m agonists methadone, fentanyl, and hydrocodone exerted qualitatively similar dose-dependent effects on ICSS, manifested as the exclusive facilitation of ICSS at relatively low doses and emergence of rate-decreasing effects at doses 10-fold higher than the lowest doses to produce facilitation (Fig. 3) . The lower efficacy m agonists buprenorphine and nalbuphine also produced exclusive facilitation of ICSS at relatively low doses; however, in contrast to the higher efficacy m agonists, buprenorphine and nalbuphine continued to produce exclusive facilitation of ICSS at doses up to 10-fold (buprenorphine) and 30-fold (nalbuphine) higher than the lowest doses to produce facilitation ( Fig. 4a-d) . The opioid antagonist naltrexone did not alter ICSS at a dose sufficient to antagonize methadone-induced facilitation of ICSS ( Fig. 4e and f) . The m agonists differed in their potencies to facilitate ICSS (fentanyl = buprenorphine > methadone = nalbuphine > hydrocodone), and Fig. 5 shows that they also differed in their time courses to facilitate ICSS. Methadone, fentanyl, hydrocodone, and nalbuphine all produced peak facilitation of ICSS at the earliest time tested (10 min), whereas buprenorphine had a slower onset of action (peak facilitation at 100 min). Speed of offset was the fastest for fentanyl (off after 30 min), followed by hydrocodone and nalbuphine (off at 100 min), methadone (off at 180 min), and buprenorphine (off at 24 h). Finally, offset of ICSS facilitation was followed by transient but significant decreases in ICSS for all drugs, except buprenorphine. Treatment with vehicle (saline) did not produce significant changes in ICSS at any time point.
Further experiments were conducted in four other groups of rats, and the control ICSS parameters for each group are shown in Table 4 . Figure 6 shows the time course of the effects produced in a group of opioid-experienced rats by 1.0 mg/kg buprenorphine, a dose 100-fold higher than the lowest dose to facilitate ICSS in the experiment above. The main effect was facilitation of low ICSS rates maintained by low frequencies of brain stimulation (63-100 Hz). Rate-decreasing effects were observed at some time points at high frequencies (e.g. 158 Hz at 100 min), but even this high dose of buprenorphine failed to reduce ICSS to the degree observed with high doses of higher efficacy m agonists (Fig. 3) . As expected, this high dose of buprenorphine had a faster rate of onset and longer duration of action than that observed with the Role of opioid efficacy in ICSS Altarifi et al. 683 lower buprenorphine dose shown in Fig. 5 . Next, another group of opioid-experienced rats received morphine alone (10 mg/kg), nalbuphine alone (1.0 mg/kg), or a combina-tion of both drugs (Fig. 7) . In this group of rats, morphine alone decreased ICSS, nalbuphine alone had no effect on ICSS, and nalbuphine pretreatment completely blocked the rate-decreasing effects of morphine. Figure 8 shows the effects of methadone and nalbuphine in two separate groups of opioid-naive rats. Relative to their effects in the initial group of opioid-experienced rats shown in Figs 3 and 4, methadone and nalbuphine produced weaker ICSS facilitation, and methadone produced more potent ICSS depression. For example, 1.0 mg/kg methadone facilitated low rates of ICSS maintained by low frequencies of brain stimulation in opioid-experienced rats (Fig. 3 ), but only depressed high rates of ICSS maintained by high frequencies of brain stimulation in opioid-naive rats (Fig. 8) . Similarly, nalbuphine produced greater magnitudes of ICSS facilitation across a broader range of frequencies in opioid-experienced rats (Fig. 4 ) than in opioid-naive rats (facilitation only at 89 Hz after 0.32 and 10 mg/kg; Fig. 8 ). Notably, nalbuphine did not significantly decrease ICSS at any dose in opioid-naive rats, but this absence of rate-decreasing effects was not associated with enhanced expression of rate-increasing effects relative to methadone.
Discussion
m-opioid receptor agonists such as morphine can either facilitate or depress ICSS, and previous opioid exposure can increase the expression of abuse-related ICSS facilitation. This study tested the hypothesis that ratedecreasing effects require the activation of a larger relative fraction of m receptors, and hence are more vulnerable to tolerance-associated reductions in receptor density, than rate-increasing effects. In contrast to this hypothesis, the irreversible m antagonist b-FNA failed to show higher potency to block rate-decreasing versus the rate-increasing effects of morphine, and no dose of b-FNA produced a tolerance-like enhancement in the expression of ICSS facilitation. Similarly, in opioid-naive rats, a reduction in the efficacy of m agonists was associated with a decreased expression of rate-decreasing effects, but not a tolerance-like enhancement in ICSS facilitation. Taken together, these results indicate that opioid exposure increases the expression of abuse-related ICSS facilitation by mechanisms other than overall reductions in m-opioid receptor density.
Effects of repeated morphine
In the present series of experiments, studies with cumulative morphine replicated three key phenomena observed in previous studies with individual morphine doses (Kornetsky and Esposito, 1979; Carlezon and Wise, 1993; Easterling and Holtzman, 1997; Craft et al., 2001; Jha et al., 2004; Altarifi and Negus, 2011) . First, morphine exerted both rate-increasing and rate-decreasing effects. Second, rate-increasing effects predominated at lower morphine doses, and rate-decreasing effects emerged and predominated at higher morphine doses. Thus, the dose-effect curve for the effects of morphine on the overall rates of ICSS showed an inverted-U shape. Third, repeated daily morphine treatment enhanced the expression of the rate-increasing effects of morphine while producing tolerance to rate-decreasing effects. This study tested the hypothesis that opioid agonist-induced rate-decreasing effects require the activation of a larger relative fraction of m receptors, and hence are more vulnerable to tolerance-associated reductions in receptor density, than rate-increasing effects.
Antagonism of morphine by b-funaltrexamine
As one approach to test this hypothesis, the effects of cumulative morphine were redetermined in different groups of rats after pretreatment with the m-selective antagonist b-FNA. Because of its irreversible binding to m receptors, b-FNA has the effect of reducing functional m receptor density (Martin et al., 1993) , and b-FNA and other irreversible antagonists have been widely used to examine both the relative efficacies of different m agonists (Comer et al., 1992; Walker et al., 1998 Walker et al., , 1999 Negus et al., 2003) and the efficacy requirements of different effects produced by a given m agonist (Zernig et al., 1994; Walker et al., 1995 Walker et al., , 1999 . For example, m agonists can produce thermal antinociception against both low-intensity and high-intensity noxious stimuli, and irreversible antagonists generally produce greater or more potent antagonism of antinociception at higher intensities (Zernig et al., 1994; Walker et al., 1995) , consistent with other evidence to suggest higher efficacy requirements for m agonist antinociception at higher noxious stimulus intensities (Morgan et al., 1999) . As another example, equivalent doses of b-FNA produced greater antagonism of morphine antinociception than of morphine-induced depression of food-maintained operant responding in Long-Evans rats, and these results were interpreted to indicate higher efficacy requirements for antinociception, the effect more vulnerable to the irreversible antagonist (Walker et al., 1999) .
In the present study, the hypothesis of higher efficacy requirements for rate-decreasing than the rate-increasing effects of m agonists predicted that b-FNA would have higher potency to antagonize rate-decreasing effects and that the b-FNA dose could be titrated to selectively attenuate the rate-decreasing effects of morphine and enhance the expression of rate-increasing effects. However, there was no evidence that b-FNA was more potent in blocking depression than facilitation of ICSS. If anything, the reverse was observed, with the lowest b-FNA dose (0.32 mg/kg) blocking the expression of significant facilitation while having little effect on morphine-induced depression of ICSS. Moreover, although b-FNA dose-dependently blocked the ratedecreasing effects of morphine, no dose of b-FNA produced a reciprocal enhanced expression of rateincreasing effects. Overall, then, these results with b-FNA do not support the hypothesis that morphineinduced depression of ICSS has higher efficacy requirements at m receptors than morphine-induced facilitation of ICSS.
Effects of l agonists that vary in efficacy
Drugs with varying efficacies at m receptors enable a second approach to dissociate the efficacy requirements of different effects produced by m agonists. For example, low-efficacy m agonists such as nalbuphine and buprenorphine often produce antinociception against low-intensity, but not high-intensity noxious thermal stimuli, whereas higher efficacy m agonists such as morphine, fentanyl, and methadone are more likely to produce antinociception against both low-intensity and highintensity noxious stimuli (Morgan et al., 1999; Negus and Mello, 1999; Cook et al., 2000) . Such data provide one source of evidence to suggest that antinociception against low-intensity noxious stimuli has lower efficacy requirements than antinociception against high-intensity noxious stimuli.
In the present study, in opioid-experienced rats, the lowefficacy m agonists nalbuphine and buprenorphine facilitated ICSS across a broad range of doses, but produced little or no depression of ICSS, whereas higher efficacy m agonists produced biphasic facilitation and depression of ICSS. Moreover, nalbuphine pretreatment antagonized the rate-decreasing effects of morphine, although nalbuphine alone failed to facilitate ICSS in this group. These findings are superficially consistent with lower efficacy requirements for facilitation than depression of ICSS and not in agreement with the implications of the b-FNA studies described above. However, initial results with different efficacy m agonists (Figs 3-5) were obtained in opioid-experienced rats, albeit using a twice per week testing regimen intended to minimize opioid tolerance. Given both (a) the known potential for opioid exposure to attenuate ICSS-depressing effects (Altarifi and Negus, 2011;  cumulative morphine data in Fig. 1) and (b) the discrepancy with b-FNA experiments, a follow-up study was carried out with nalbuphine and methadone in opioid-naive rats. Methadone was more potent in depressing ICSS and both drugs were less effective in facilitating ICSS in opioid-naive than in opioid-experienced rats. The differences in the effects of methadone between opioid-naive and opioid-experienced Role of opioid efficacy in ICSS Altarifi et al. 689 rats indicate that even intermittent opioid exposure associated with twice per week testing was sufficient to produce tolerance to ICSS depression similar to that observed with more intensive daily regimens of morphine treatment (Altarifi and Negus, 2011 ; cumulative morphine data in Fig. 1 ). Moreover, these results suggest that opioid exposure also augments the expression of the rateincreasing effects produced by low-efficacy m agonists such as nalbuphine that do not reliably facilitate ICSS in naive rats. Indeed, nalbuphine was tested in three different groups of rats in this study, and facilitation of ICSS was greatest in the group with the greatest extent of opioid exposure before nalbuphine testing. Overall, the limited ability of nalbuphine to facilitate ICSS in rats with little or no history of opioid exposure fails to support the hypothesis that opioid-induced facilitation of ICSS has lower efficacy requirements at m receptors than opioid-induced depression of ICSS.
Effects of opioid exposure versus irreversible antagonism
One premise for the experimental design of this study was that both opioid exposure and b-FNA might produce qualitatively similar effects on m agonist-induced changes in ICSS by decreasing the functional density of m-opioid receptors. However, the differing effects of these treatments indicate that they produced effects on distinct receptor populations mediating m agonistinduced facilitation and depression of ICSS. Consistent with this possibility, previous studies have reported different effects of treatment with chronic morphine or b-FNA on the anatomical distribution of m agoniststimulated GTPgS binding in the rat brain (Sim et al., 1996; Martin et al., 1997) . Thus, a regimen of chronic morphine selectively decreased this measure of functional m-opioid receptors in brain stem areas, including periaqueductal gray, but not in forebrain areas, including the striatum and the nucleus accumbens. Conversely, b-FNA produced a different anatomical profile of effects that included decreases in functional m receptors in both the brain stem and the forebrain areas, with some of the greatest reductions observed in the striatum and the nucleus accumbens. The anatomical differences in the effects of chronic morphine and b-FNA on m receptor function may be relevant to ICSS, because a previous brain mapping study has reported that morphine produced primarily depression of ICSS after a local injection into brain stem areas proximal to the periaqueductal gray and primarily facilitation of ICSS after an intracerebral injection in the forebrain areas proximal to the striatum (Broekkamp et al., 1976) . Taken together, these studies suggest that brain stem m receptors mediating ICSS depression might be inactivated by either chronic morphine or b-FNA, whereas forebrain m receptors mediating ICSS facilitation might be inactivated by b-FNA, but not by chronic morphine.
A second pharmacological factor that might contribute to the differential effects of opioid exposure versus b-FNA is the contribution of non-m-opioid receptors to opioid agonist effects. For example, both k-opioid and d-opioid receptor agonists depress ICSS (Todtenkopf et al., 2004; Do Carmo et al., 2009; Negus et al., 2010) , raising the theoretical possibility that d or k receptor activation might contribute to the rate-decreasing effects of opioid agonists such as morphine that are selective for m receptors, but retain lower affinity for d and k receptors (Emmerson et al., 1994; Raynor et al., 1994; Toll et al., 1998) . At least two findings in this study argue against this possibility. First, m agonists with greater m selectivity than morphine [e.g. fentanyl; (Emmerson et al., 1994; Raynor et al., 1994; Toll et al., 1998) ] produced a morphine-like biphasic effect on ICSS, suggesting that the activation of the m receptor is sufficient to produce both facilitation and depression of ICSS. Second, both morphine-induced facilitation and depression of ICSS were fully antagonized by the m-selective antagonist b-FNA, suggesting that m receptors are necessary for both morphine effects.
A third factor that may contribute to the different effects of chronic opioid exposure versus b-FNA is that the former may produce opioid dependence in addition to tolerance. In ICSS, opioid dependence may be expressed as depression of ICSS during periods of opioid withdrawal (Schaefer and Michael, 1983; Altarifi and Negus, 2011) .
In the present study, withdrawal-associated depression of ICSS was apparent both after dissipation of the rateincreasing effects produced by acute treatment with most opioid agonists (Fig. 5) or after repeated treatment with morphine (Table 2) . Accordingly, the increased expression of rate-increasing effects produced by m agonists in opioid-experienced subjects may partly be because of a reversal of withdrawal-associated depression in baseline ICSS.
A final nonpharmacological consideration is that behavioral tolerance may have also contributed to the differential effects of opioid exposure and b-FNA treatment. The opportunity to engage in behavior in the presence or absence of a drug can modify the development of tolerance. For example, in an assay of food-maintained schedule-controlled behavior, tolerance to the rate-decreasing effects of morphine develops more rapidly when operant behavior occurs in the presence of morphine than when the behavior and drug administration occur in separate contexts (Sannerud and Young, 1986) . Furthermore, drug effects that disrupt the ability to fulfill reinforcement contingencies are more susceptible to the development of tolerance than are drug effects that enhance or do not disrupt rates of reinforcement (Schuster et al., 1966) . In the present study, the administration of opioid agonists always occurred in a context in which reinforcement of the operant also occurred. Thus, in opioid-experienced rats, the interaction of a history of m agonist exposure and the opportunity to engage in ICSS may contribute to the development of tolerance to rate-decreasing effects and enhanced expression of rate-increasing effects. Continued evaluation of the role of pharmacological and nonpharmacological factors in the effects of acute and repeated opioid agonist administration in ICSS may improve the usefulness of this procedure as an experimental tool for assessment of the abuse potential of opioids and other drugs.
